Etoposide

Generic Name
Etoposide
Brand Names
Etopophos, Toposar, Vepesid
Drug Type
Small Molecule
Chemical Formula
C29H32O13
CAS Number
33419-42-0
Unique Ingredient Identifier
6PLQ3CP4P3
Background

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

First Posted Date
2018-07-11
Last Posted Date
2024-10-15
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
240
Registration Number
NCT03583710
Locations
🇸🇪

Sahlgrenska University Hospital, Gothenburg, Sweden

🇸🇪

Karolinska University Hospital, Stockholm, Sweden

🇸🇪

Akademiska Sjukhuset, Uppsala, Sweden

and more 5 locations

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

First Posted Date
2018-07-11
Last Posted Date
2021-10-06
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
19
Registration Number
NCT03583424
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

First Posted Date
2018-07-11
Last Posted Date
2023-04-12
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
15
Registration Number
NCT03582475
Locations
🇺🇸

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma

First Posted Date
2018-07-09
Last Posted Date
2020-01-29
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT03579927
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

First Posted Date
2018-06-27
Last Posted Date
2022-06-22
Lead Sponsor
Swedish Medical Center
Target Recruit Count
100
Registration Number
NCT03570983
Locations
🇺🇸

Swedish Cancer Institute, Seattle, Washington, United States

Atovaquone (Mepron®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML)

First Posted Date
2018-06-26
Last Posted Date
2024-11-21
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
26
Registration Number
NCT03568994
Locations
🇺🇸

Baylor College of Medicine - Texas Childrens Hospital, Houston, Texas, United States

🇺🇸

Johns Hopkins Medicine, Baltimore, Maryland, United States

A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers

Phase 1
Active, not recruiting
Conditions
Lung Cancer
Interventions
Drug: Osimertinib
Drug: Platinum
Drug: Etoposide
First Posted Date
2018-06-26
Last Posted Date
2024-07-03
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
11
Registration Number
NCT03567642
Locations
🇺🇸

Memorial Sloan Kettering Westchester, Harrison, New York, United States

🇺🇸

Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Commack, Commack, New York, United States

and more 3 locations

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL

First Posted Date
2018-06-21
Last Posted Date
2018-06-21
Lead Sponsor
Nanfang Hospital, Southern Medical University
Target Recruit Count
80
Registration Number
NCT03564704
Locations
🇨🇳

Department of Hematology, Nanfang Hospital, Guangzhou, Guangdong, China

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL

First Posted Date
2018-06-12
Last Posted Date
2018-06-12
Lead Sponsor
Nanfang Hospital, Southern Medical University
Target Recruit Count
70
Registration Number
NCT03553238
Locations
🇨🇳

Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

First Posted Date
2018-05-23
Last Posted Date
2024-12-05
Lead Sponsor
Children's Oncology Group
Target Recruit Count
537
Registration Number
NCT03533582
Locations
🇺🇸

Henry Ford Health Saint John Hospital, Detroit, Michigan, United States

🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

🇺🇸

Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 202 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy